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Abstract
Background: Postoperative complications are of great relevance in daily clinical practice, and the gut microbiome
might play an important role by preventing pathogens from crossing the intestinal barrier. The two aims of this
prospective clinical pilot study were: (1) to examine changes in the gut microbiome following pancreatic surgery,
and (2) to correlate these changes with the postoperative course of the patient.
Results: In total, 116 stool samples of 32 patients undergoing pancreatic surgery were analysed by 16S-rRNA gene
next-generation sequencing. One sample per patient was collected preoperatively in order to determine the baseline
gut microbiome without exposure to surgical stress and/or antibiotic use. At least two further samples were obtained
within the first 10 days following the surgical procedure to observe longitudinal changes in the gut microbiome.
Whenever complications occurred, further samples were examined.
Based on the structure of the gut microbiome, the samples could be allocated into three different microbial
communities (A, B and C). Community B showed an increase in Akkermansia, Enterobacteriaceae and Bacteroidales as
well as a decrease in Lachnospiraceae, Prevotella and Bacteroides. Patients showing a microbial composition resembling
community B at least once during the observation period were found to have a significantly higher risk for developing
postoperative complications (B vs. A, odds ratio = 4.96, p < 0.01**; B vs. C, odds ratio = 2.89, p = 0.019*).
Conclusions: The structure of the gut microbiome is associated with the development of postoperative complications.
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Background
Despite the constant improvement in operation tech-
niques, intensive care and standardised antibiotic use,
postoperative complications are still a significant problem
in daily clinical practice. Over the past years, the use of
next-generation sequencing (NGS) has changed our
perception and understanding of the structure and func-
tion of the microbiome in various organ systems. The gut
microbiome has been shown to play an important role in
preventing opportunistic and nosocomial infections,
which are becoming more frequent due to widespread
antibiotic use [1–3]. Under normal conditions, specific
members of the normally abundant gut microbiota inter-
act with low abundance pathobiota and prevent them
from crossing the intestinal barrier. At the same time, the
gut microbiome composition appears to reflect the
efficiency of our immune system to react to invasive path-
ogens [4–6]. The use of NGS allows new insights into the
complex composition of the intestinal flora and its
reaction to external influences. Several studies have shown
a correlation between the composition of the gut micro-
biome and certain diseases, such as obesity, irritable bowel
syndrome and Crohn’s disease, as well as disease severity
[7–9]. Additionally, the gut microbiome appears to change
dramatically in critically ill patients. A significant de-
crease in bacterial diversity together with a flare-up
of problematic bacteria such as Clostridium difficile
and vancomycin-resistant enterococci has been
* Correspondence: Felix.Schmitt@med.uni-heidelberg.de
1Department of Anesthesiology, Heidelberg University Hospital, 110, Im
Neuenheimer Feld, D-69120 Heidelberg, Germany
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Schmitt et al. BMC Microbiology           (2019) 19:42 
https://doi.org/10.1186/s12866-019-1399-5
observed [10–16]. Moreover, it should be acknowl-
edged that anti-infective treatment strategies (e.g.,
antibiotics and antimycotics) are able to aggravate mi-
crobial imbalance, paving the way for further surgical
site infections [5]. Unfortunately, our ability to predict
postoperative complications is limited [17], and the extent
to which surgical stress and perioperative antibiotic use
influence the gut microbiome are yet to be clarified. Simi-
larly, we are still unclear as to whether changes in the
microbiome can be used to predict complications during
the postoperative clinical course. Thus, this prospective, ob-
servational, clinical study aimed to examine changes in the
gut microbiome, as well as the consequences on the post-
operative course, after pancreatic surgery. Our working hy-
pothesis was that (1) the gut microbiome experiences
major changes in the perioperative setting, and (2) a change
in bacterial diversity or composition might have an impact
on the incidence of postoperative complications.
Results
Patient characteristics
In total, 32 patients undergoing pancreatic surgery were in-
cluded in the final evaluation, of whom 17 patients suffered
postoperative complications and 15 had a non-complicated
clinical course. Patients with a non-complicated clinical
course were significantly younger and had a lower Ameri-
can Society of Anesthesiologists (ASA) status than those
that suffered complications. Most clinical baseline charac-
teristics prior to surgery (e.g., cardiovascular risk factors) as
well as perioperative factors (surgery duration, type of oper-
ation and blood loss) showed no significant differences
between the complicated and non-complicated groups.
However, in the postoperative period, patients in the com-
plicated group showed significantly increased C-reactive
protein (CRP) levels, a higher leucocyte count, prolonged
hospital stay and longer time in the intensive care unit
(ICU) (Table 1). The complicated group was further subdi-
vided into two groups depending on whether they experi-
enced medical (n = 5) or surgical (n = 14) complications.
Two patients suffered from both a medical and surgical
complication; therefore, both patients were allocated into
both the medical and surgical group. Two patients in the
medical group suffered from a lung artery embolism,
requiring ICU treatment. Three patients displayed signs of
an infection (e.g., urinary tract infection) and were treated
with antibiotics. In the group of patients that experienced a
surgical complication, six patients were treated with percu-
taneous drainage and two patients underwent re-operation
due to a postoperative pancreatic fistula. Six patients
were affected by delayed gastric emptying, whereas
none of the patients suffered from postoperative
bleeding. All 32 patients survived the 90-day observa-
tion period. For a better overview, Fig. 1 summarizes
all postoperative complications.
Structure and longitudinal evolution of the gut
microbiome
The gut microbiome in the studied cohort of patients
was highly variable. The most abundant phyla in the
dataset were Bacteroidetes, Firmicutes and Proteobac-
teria, and to a lesser extent,Verrucomicrobia and Actino-
bacteria (Fig. 2a). Based on the Morisita-Horn index,
samples from the same patients were more closely
related to each other than to samples from a different
patient (Wilcoxon test, W = 184,400, p < 0.001***). We
observed a significant correlation between clinical
parameters and the PCoA axis, whereby the leucocyte
count was positively correlated with axis 1, while the
CRP level, the presence of a postoperative complication
and the postoperative sample period were positively cor-
related with axes 1 and 2 (Fig. 2b). We observed that the
majority of patients suffering from complications, showed
microbial community B at least once during the postoper-
ative period. As depicted in the alluvial graph, all patients
presenting community B at the pre-operative time point
continue to show a similar community during the postop-
erative period. Furthermore, the majority of patients with
a complicated postoperative course harboured community
B during the post-operation period (Fig. 2c). We did not
observe any significant differences in species richness or
alpha-diversity between samples from patients with or
without postoperative complications. These results are
consistent with those obtained using the PERMANOVA
analysis indicating no significant change in the structure
of the microbiome of samples from patients with or
without postoperative complications. Nonetheless, the
longitudinal evolution of the gut microbiome indi-
cated a trend toward slight dysbiosis in the compli-
cated cohort (Fig. 3).
Distinct microbial communities of the gut microbiome
Clustering analysis using the partitioning around medoid
method indicated that based on the microbiome structure
three microbial communities best described the cohort,
namely community A, B and C (Fig. 2a). Community B was
composed of samples from the upper right side of the
PCoA, whereas A and C clustered to the right and bottom
left of the PCoA, respectively (Fig. 2b). These communities
did not show significant differences in regard to
alpha-diversity and richness, but were hallmarked by a
different microbial structure (Fig. 2a). The only significant
differences between community A and C were increased
Prevotella and Lachnospiraceae in community A and
increased Bacteroides and Faecatitalea in community C.
Community B displayed an increase in Akkermansia, Aero-
monas, Enterobacteriaceae and Bacteroidales and a de-
crease in Lachnospiraceae, Prevotella, Faecatitalea and
Bacteroides (Fig. 4). At the phylum level, only community B
and C showed a moderate but significant (p < 0.01**)
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Table 1 Patients’ characteristics
Non-complicated Medical
complication
Surgical
complication
All
complications
p-value non-comp.
vs. med. Comp.
p-value non-comp.
vs. surg. Comp.
p-value non-comp.
vs. all comp.
Number 15 51 141 17
Age [years] 59.0 (50.0–63.5) 75.0 (75.0–75.0) 68.5 (63.3–74.0) 69.0 (62–75) 0.013* 0.009** 0.002**
ASA status 2.0 (2.0–2.0) 2.0 (2.0–3.0) 3.0 (2.0–3.0) 3.0 (2.0–3.0) 0.327 0.014* 0.021*
Cardiovascular risk factors
Coronary heart disease 2 (13.3%) 1 (20.0%) 1 (7.1%) 1 (5.9%) 0.718 0.584 0.801
Diabetes 3 (20.0%) 2 (40.0%) 4 (28.6%) 5 (29.4%) 0.371 0.590 0.447
Arterial hypertension 5 (33.3%) 4 (80.0%) 6 (42.9%) 8 (47.1%) 0.069 0.597 0.260
Chronic renal failure 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1.000 1.000 1.000
Primary disease
Malignant 8 (53.3%) 4 (80.0%) 8 (57.1%) 11 (64.7%) 0.292 0.837 0.563
IPMN 2 (12.5%) 1 (20.0%) 6 (42.9%) 6 (35.3%) 0.718 0.075 0.123
Chronic pancreatitis 5 (33.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0.136 0.018* 0.006**
Operation
Partial
pancreaticoduodenectomy
3 (20.0%) 1 (20.0%) 3 (21.4%) 4 (23.5%) 1.000 0.924 0.940
Pylorus-preserving
pancreas head resection
5 (33.3%) 3 (60.0%) 5 (35.7%) 6 (35.3%) 0.292 0.893 0.601
Total pancreatectomy 2 (13.3%) 1 (20.0%) 0 (0.0%) 1 (5.9%) 0.718 0.157 0.410
Distal pancreatectomy 3 (20.0%) 0 (0.0%) 3 (21.4%) 3 (17.7%) 0.278 0.924 0.749
Tumour enucleation 2 (13.3%) 0 (0.0%) 3 (21.4%) 3 (17.7%) 0.389 0.564 0.841
Surgery [min] 285.0
(187.5–345.0)
240.0
(240.0–330.0)
217.5
(153.8–337.5)
240.0
(165.0–330.0)
0.726 0.444 0.639
Blood loss2 [mL] 750.0
(500.0–1150.0)
700.0
(600.0–800.0)
600.0
(500.0–700.0)
600.0
(500.0–800.0)
0.965 0.273 0.393
Infusion2 [mL] 3500.0
(2500.0–4250.0)
3000.0
(3000.0–4500.0)
2750.0
(2000.0–3375.0)
3000.0
(2000.0–3500.0)
0.756 0.186 0.352
Transfusion2 [mL] 0.0 (0.0%) 0.0 (0.0%) 0.0 (0.0%) 0.0 (0.0%) 1.000 1.000 1.000
CRP3 [mg/L] 56.2
(36.4–114.8)
135.6
(79.9–151.9)
114.0
(76.9–160.7)
103.9
(74.4–153.0)
0.020* 0.004** 0.001**
Leucocytes3 [1/nL] 9.0 (7.9–10.3) 11.4 (9.0–17.4) 11.7 (76.9–
160.9)
11.4 (8.3–14.0) 0.015* 0.025* 0.007**
Hospital stay
In total [days] 10.0 (9.0–11.5) 21.0 (13.0–45.0) 27.0 (15.0–44.5) 21.0 (13.0–43.0) 0.007** 0.001** < 0.001***
Intermediate care unit
[days]
0.0 (0.0–0.0) 5.0 (0.0–23.0) 0.0 (0.0–4.8) 0.0 (0.0–5.0) 0.041* 0.245 0.095
Intensive care unit [days] 0.0 (0.0–0.0) 1.0 (0.0–1.0) 0.0 (0.0–1.0) 0.0 (0.0–1.0) 0.033* 0.059 0.027*
Postoperative complications [Clavien-Dindo classification]
Grade I 0 (0.0%) 0 (0.0%) 4 (28.6%) 4 (23.5%) 1.000 0.026* 0.059
Grade II 0 (0.0%) 3 (60.0%) 3 (21.4%) 6 (35.3%) 0.001** 0.058 0.016*
Grade III4 0 (0.0%) 0 (0.0%) 6 (42.9%) 6 (35.3%) 1.000 0.004** 0.016*
Grade IV5 0 (0.0%) 2 (40.0%) 1 (7.1%) 2 (11.8%) 0.010* 0.129 0.059
Grade V 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1.000 1.000 1.000
Data are presented as the median and interquartile range (Q1–Q3) or as count and percentage. A p-value < 0.05 was considered statistically significant and
are highlighted in boldface. Concerning symbolism and higher orders of significance: p < 0.05 *, p < 0.01 **, p < 0.001 ***. ASA status, American Society of
Anesthesiologists physical status classification system; IPMN, intraductal papillary mucinous neoplasm; CRP, C-reactive protein. 1Two patients suffered from
medical and surgical complications, therefore both have been allocated into the medical as well as the surgical complication group; 2total measured
intraoperatively; 3postoperative observation period; 4includes grades IIIa and IIIb; 5 includes grades IVa and IVb
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structural difference in the ratio of Firmicutes/Bacteroidetes
(F/B ratio) compared to healthy volunteers (Fig. 5).
Microbial community B is associated with a higher
complication rate
Patients with community B in the pre- and/or postoper-
ative period showed no significant differences in their
clinical baseline characteristics prior to surgery (primary
disease, age, ASA status and cardiovascular risk factors)
as well as perioperative factors (surgery time and blood
loss) compared to those patients that showed another
composition of microbial community. Partial pancreati-
coduodenectomy was the only type of operation that
was more frequent in patients with community B
(Table 2). Accordingly, samples belonging to community
B were more often associated with bowel resection sur-
gical procedures (B vs. A, odds ratio = 5.47, p < 0.01**; B
vs. C, odds ratio = 2.96, p = 0.035*). Nevertheless, we did
not observe any association between a specific type of
operation and development of complications (odds ratio
= 1.09, p = 1.000).
Patients with community B showed significantly higher
CRP levels and leucocyte counts in the postoperative
period, as well as a significantly prolonged hospital stay
and increased requirement for ICU treatment (Table 2).
Furthermore, samples from community B were more fre-
quently associated with postoperative complications (B vs.
A, odds ratio = 4.96, p < 0.01**; B vs. C, odds ratio = 2.89,
p = 0.019*) and we observed a positive association between
patients harbouring community B at least once during the
study period and the development of a complication (odds
ratio = 8.60, p < 0.01**; Fig. 2c). However, an occurrence of
community B prior to surgery was not mandatory for the
development of postoperative complications. Patients
harbouring community B only during the postoperative
period also showed increased complication rates as well as
the same clinical characteristics as those patients present-
ing community B prior to surgery (e.g., age, ASA status,
CRP levels, leucocyte count and hospital stay; Table 3).
The predicted functions of the microbiota in community B
were associated with significantly increased metabolism
and transporter activity. We also observed an increase in a
few functions involving the secretion system, the prokary-
otic defence system and bacterial toxins (Fig. 6).
Primary disease
The postoperative histological results revealed in 19
patients a malignant pancreatic tumour, in 8 patients an
intraductal papillary mucinous neoplasm (IPMN) and in 5
patients signs of a chronic pancreatitis. The incidence of
postoperative complications did not differ significantly
between the malignant and the IPMN group. In the chronic
pancreatitis group no postoperative complications occurred
(Table 1). The primary disease seemed to have no
influence on the pre- and postoperative microbial com-
munities (Tables 2, 3). Additional file 1: Table S1 gives also
a more detailed overview about the several tumour stages
and the occurrence of postoperative complications and
the incidence of community B.
Discussion
The composition of the gut microbiome, respectively the
included members of the microbial community, play an
important role by interacting with pathogens and pre-
venting them from crossing the intestinal barrier [4–6].
Recent studies have established that the gut micro-
biome is dramatically altered in critically ill patients,
in particular, decreased bacterial diversity during their
Fig. 1 Postoperative complications, subdivided into two groups depending on whether they experienced medical (n = 5, reddish coloured) or
surgical (n = 14, bluish coloured) complications
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stay in the ICU. This stress situation not only led to
dysbiosis, but also the rampant growth of pathogens
[10–16]. Therefore, the present study aimed to exam-
ine changes in the gut microbiome and the potential
influence on the postoperative course in patients
undergoing pancreatic surgery.
We were able to discriminate three separate microbial
communities of the gut microbiome, each with a very
A
B C
Fig. 2 Microbial structure of the gut microbiome in the different microbial communities. a Microbial composition of the different microbial
communities are represented at the phylum level on the left side and at the operational taxonomic unit (OTU) level on the right side. Only the 35
most abundant OTUs are represented. The remaining microbiota are included in the group “other”. b Microbial composition visualised by principal
coordinate analysis (PCoA). Different colours correspond to the distinct microbial communities, where blue represents community A, red is community
B and yellow is community C. Shapes correspond to the complication status, with circles representing no complication and triangles representing
complications. Correlated clinical parameters and alpha-diversity indices are indicated by crosses. c Alluvial graph showing the evolution of the
patients’ microbiome from the pre- to the post-operative period (group allocation based on colonisation with community B at least once during the
distinct timespan) and association to the complication status
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different composition. All patients harboring community
B already at the pre-operative period were also carrying
this community during the post-operative period indicat-
ing a high stability and resistance of this microbiome
type. Furthermore, community B was also associated
with higher CRP levels, an increased leukocyte count,
more frequent incidence of postoperative complications
as well as prolonged hospitalisation. Interestingly, this
was still the case when a patient was found to harbour
community B only once during the observation period.
Based on the findings of previous studies with critically
ill patients, we expected significant differences with regard
to the alpha-diversity and richness in patients undergoing
pancreatic surgery. Surprisingly, we did not observe this
dramatic effect in our cohort of patients. Also, in the com-
plicated group, gut microbiome patterns showed only
slight changes toward dysbiosis. Both groups revealed a
typical gut microbiome composition despite various
external factors, such as systemic antibiotic use during
surgery, indicating a stable and healthy gut microbiome
[18]. However, there were large individual differences in
the composition of the gut microbiome among patients at
baseline (prior to surgery), as well as over the longitudinal
course. Some patients showed large changes in the struc-
ture of their microbiome during the postoperative period,
whereas others changed only marginally. This is due to
the fact that patients previously bearing community B
were not undergoing major changes in their microbiome
structure while the two other communities were more
prone to changes in their composition. Moreover, we were
able to show that different samples from the same patient
were more similar to each other than they were in com-
parison to samples from other patients. These results sug-
gest that individual patients not only have a unique
microbiome, but also react in a unique way to exposure to
surgical stress and antibiotics. Therefore, we conclude that
changes in richness and abundance, in addition to the
overall microbiome structure, were factors correlated with
a complicated clinical course.
Previous studies have suggested that the ratio of Firmi-
cutes/Bacteroidetes (F/B-ratio) can be used as a surro-
gate marker for the outcome of critically ill ICU patients
A B C
Fig. 3 Longitudinal changes in the gut microbiome in regard to (a) distance, (b) alpha-diversity and (c) dominance between the pre- and post-operative
microbiome in the non-complicated and in the complicated group
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[10, 12]. The changes in F/B ratio in the current study were
not as pronounced as those reported in previous studies of
critically ill patients, which is probably due to our patient
group being more homogeneous and having less severe
diseases compared to those previously reported [10]. There-
fore, its suitability to serve as a universal surrogate for
patient outcome needs to be critically evaluated.
It has not yet been established why community B is
associated with higher postoperative complication rates.
Although alpha-diversity and richness were not signifi-
cantly different among the distinct microbial communi-
ties, the specific composition at the OTU level was
found to be different. The composition of community A
was characterized by a high abundance of Prevotella,
while community C showed an increase in Bacteroides.
Based on the results of Arumugam et al., community A
resembles the previous described enterotype 2 and com-
munity C resembles enterotype 1 [19]. Interestingly, the
composition of community B differs from these previous
reported results. The composition of community B was
characterised, among others, by an increase in Akker-
mansia that belongs to the Verrucomicrobia phylum
which degrade intestinal gut mucin as their sole carbon
and nitrogen source [20]. The mucin layer of the intes-
tinal gut has an important function as it acts as a phys-
ical barrier to protect epithelial cells from pathogen
invasion [21, 22]. Animal experiments have shown a rise
in mucin production, along with an increase in Akker-
mansia in the gut microbiome under pro-inflammatory
conditions [23] and a protective effect on the epithelium
[24, 25]. The increase in Enterobacteriaceae, which are
usually located in the small intestine, remains unclear.
However, this phenomenon has recently been described
for patients undergoing Roux-en-Y gastric bypass oper-
ation due to acidity changes in the bowel milieu [5]. In
contrast Lachnospiraecae were decreased, normally asso-
ciated with resistance against colonisation by more
pathogenic bacteria including Clostridium difficile [26],
which might indicate an increased susceptibility of the
intestinal flora.
Fig. 5 The Firmicutes/Bacteroidetes ratio in our cohort was compared
to 235 healthy volunteers for whom V4 amplicon was available on
the human microbiome project (HMP) database. The Firmicutes/
Bacteroidetes ratio was calculated based on the read counts
B C A
Fig. 4 Differential abundance of each operational taxonomic unit (OTU) analysed by negative binomial distribution, represented in a heatmap for
significant differential abundant OTUs. The mean abundance was normalised within each OTU to the maximal values. The colour code is from yellow
(low abundance, 0) to blue (maximal abundance, 1). Green rectangles represent a significant differential abundance between microbial communities A
and B, red squares represent a significant differential abundance between microbial communities A and C, and cyan squares represent a significant
differential abundance between microbial communities B and C. The OTUs are named according to their genus classification
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Using Tax4Fun software to predict the potential func-
tions of the gut microbiome in the different communi-
ties, significant increases in metabolism and transporter
activity were observed which is consistent with the
above-mentioned changes in community B. Moreover,
an increase in functions involved with the secretion
Table 2 Patients’ characteristics grouped by colonisation status (non-community B vs. community B)
Non-community B Community B p-value non- community B.
vs. community B
Number 13 19
Age [years] 62.0 (51.0–68.0) 67.0 (58.0–75.0) 0.150
ASA status 2.0 (2.0–2.0) 3.0 (2.0–3.0) 0.070
Cardiovascular risk factors
Coronary heart disease 1 (7.7%) 2 (10.5%) 0.787
Diabetes 3 (23.1%) 5 (26.3%) 0.835
Arterial hypertension 5 (38.5%) 8 (42.1%) 0.837
Chronic renal failure 0 (0.0%) 0 (0.0%) 1.000
Primary disease
Malignant 6 (46.2%) 13 (68.4%) 0.208
IPMN 3 (23.1%) 5 (26.3%) 0.835
Chronic pancreatitis 4 (30.8%) 1 (5.2%) 0.051
Operation
Partial pancreaticoduodenectomy 0 (0.0%) 7 (36.8%) 0.013*
Pylorus-preserving pancreas head resection 5 (38.0%) 6 (31.6%) 0.687
Total pancreatectomy 2 (15.4%) 1 (5.3%) 0.335
Distal pancreatectomy 3 (23.1%) 3 (15.8%) 0.604
Tumour enucleation 3 (23.1%) 2 (10.5%) 0.337
Surgery [min] 195.0 (180.0–285.0) 315.0 (210.0–345.0) 0.273
Blood loss1 [mL] 600.0 (200.0–1000.0) 700 (500–950) 0.630
Infusion1 [mL] 3000.0 (2500.0–4000.0) 3000.0 (2500.0–4000.0) 0.684
Transfusion1 [mL] 0.0 (0.0–0.0) 0.0 (0.0–0.0) 1.000
CRP2 [mg/L] 73.2 (36.1–105.1) 102.7 (51.6–155.0) 0.006**
Leucocytes2 [1/nL] 9.0 (7.8–9.9) 11.1 (8.4–13.8) 0.022*
Hospital stay
In total [days] 11.0 (9.0–14.0) 15.0 (11.0–36.5) 0.030*
Intermediate care unit [days] 0.0 (0.0–0.0) 0.0 (0.0–3.0) 0.439
Intensive care unit [days] 0.0 (0.0–0.0) 0.0 (0.0–1.0) 0.032*
Postoperative complications [Clavien-Dindo classification]
Total number 3 (23.1%) 14 (73.7%) 0.005**
Grade I 2 (15.4%) 2 (10.5%) 0.683
Grade II 1 (7.7%) 5 (26.3%) 0.185
Grade III3 0 (0.0%) 6 (31.6%) 0.044*
Grade IV4 0 (0.0%) 2 (10.5%) 0.227
Grade V 0 (0.0%) 0 (0.0%) 1.000
Outcome
Survivor 90 days 13 (100.0%) 19 (100.0%) 1.000
Data are presented as the median and interquartile range (Q1–Q3) or as count and percentage. A p-value < 0.05 was considered statistically significant and are
highlighted in boldface. Concerning symbolism and higher orders of significance: p < 0.05 *, p < 0.01 **, p < 0.001 ***. ASA status, American Society of
Anesthesiologists physical status classification system; IPMN, intraductal papillary mucinous neoplasm; CRP, C-reactive protein. 1Two patients suffered from
medical and surgical complications, therefore both have been allocated into the medical as well as the surgical complication group; 2total measured
intraoperatively; 3postoperative observation period; 4includes grades IIIa and IIIb; 5includes grades IVaand IVb
Schmitt et al. BMC Microbiology           (2019) 19:42 Page 8 of 13
system, prokaryotic defence system and bacterial toxins
was observed in community B. The results of this pre-
dictive analysis and the changes in the gut microbiome
may indicate a shift toward a more competitive and
virulent microbial community. However, it remains un-
clear whether the described changes represent a defence
mechanism of the human immune system to prevent the
invasion of microbes [27], or whether the changes
Table 3 Patients’ characteristics grouped by colonisation status (non- community B vs. community B) and subdivided by the
time-point of occurrence (pre- and/or postoperative period)
Pre and post community B Post community B p-value pre and post community B
vs. post community B
Number 7 12
Age [years] 64.0 (58.5–67.0) 70.0 (58.5–75.0) 0.445
ASA status 2.0 (2.0–2.5) 3.0 (2.0–3.0) 0.118
Cardiovascular risk factors
Coronary heart disease 0 (0.0%) 2 (16.7%) 0.253
Diabetes 2 (28.6%) 3 (25.0%) 0.865
Arterial hypertension 2 (28.6%) 6 (50.0%) 0.361
Chronic renal failure 0 (0.0%) 0 (0.0%) 1.000
Primary disease
Malignant 4 (57.1%) 9 (75.0%) 0.419
IPMN 3 (42.9%) 2 (16.7%) 0.211
Chronic pancreatitis 0 (0.0%) 1 (8.3%) 0.433
Operation
Partial pancreaticoduodenectomy 4 (57.1%) 3 (25.0%) 0.161
Pylorus-preserving pancreas head resection 1 (14.3%) 5 (41.7%) 0.216
Total pancreatectomy 1 (14.3%) 0 (0.0%) 0.179
Distal pancreatectomy 1 (14.3%) 2 (16.7%) 0.891
Tumour enucleation 0 (0.0%) 2 (16.7%) 0.253
Surgery [min] 330.0 (315.0–360.0) 240.0 (176.3–333.8) 0.149
Blood loss1 [mL] 750.0 (600.0–1300.0) 600.0 (500.0–800.0) 0.251
Infusion1 [mL] 3000.0 (2750.0–4250.0) 3000.0 (2375.0–3750.0) 0.491
Transfusion1 [mL] 0.0 (0.0–0.0) 0.0 (0.0–0.0) 1.000
CRP2 [mg/L] 147.5 (79.2–175.8) 86.7 (45.5–148.0) 0.178
Leucocytes2 [1/nL] 12.5 (8.6–14.0) 10.4 (8.0–12.9) 0.370
Hospital stay
In total [days] 15.0 (10.5–32.0) 16.0 (11.8–33.8) 0.641
Intermediate care unit [days] 0.0 (0.0–5.5) 0.0 (0.0–0.3) 0.539
Intensive care unit [days] 1.0 (0.0–1.5) 0.0 (0.0–1.0) 0.295
Postoperative complications [Clavien-Dindo classification]
Grade I 3 (42.9%) 2 (16.7%) 0.211
Grade II 1 (14.3%) 5 (41.7%) 0.363
Grade III3 0 (0.0%) 2 (16.7%) 0.253
Grade IV4 0 (0.0%) 0 (0.0%) 1.000
Grade V 1 (14.3%) 1 (8.3%) 0.683
Outcome
Survivor 90 days 13 (100.0%) 19 (100.0%) 1.000
Data are presented as the median and interquartile range (Q1–Q3) or as count and percentage. A p-value < 0.05 was considered statistically significant and are
highlighted in boldface. Concerning symbolism and higher orders of significance: p < 0.05 *, p < 0.01 **, p < 0.001 ***. ASA status, American Society of
Anesthesiologists physical status classification system; IPMN, intraductal papillary mucinous neoplasm; CRP, C-reactive protein. 1total measured intraoperatively;
2postoperative observation period; 3includes grades IIIa and IIIb; 4includes grades IVa and IVb
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themselves cause this problem. Furthermore, these func-
tions are only prediction based on 16S profiles and
should be validated by metagenomic or metatranscrip-
tomic analyses to confirm the link between virulence fac-
tors and increased metabolism in community B.
Nevertheless, our results reveal a clear connection be-
tween the respective community of the gut microbiome
and the probability of developing a postoperative compli-
cation. Accordingly, implementation of a NGS-based
approach for the detection of changes in the gut micro-
biome should be considered in routine diagnostics. In case
of a detrimental microbial community, and assuming that
changes in the gut microbiome are a cause rather than a
consequence of postoperative complications, the avoid-
ance of microbiome altering medications (i.e. antibiotics)
and a combined individualized diet or in cases of
non-response a stool transplantation might represent a
causal therapeutic option. Where appropriate, this could
be performed in the preoperative setting to modify the
microbiome composition in order to lower the incidence
of postoperative complications.
There are several limitations that need to be addressed
in relation to the presented manuscript.
The previous described model of three several “entero-
types” by Arumugam et al. or the “microbial communities”
presented in the recent paper, have to be considered with
great caution. Because every patient will show a unique
composition of its microbial structure within a commu-
nity or “enterotype” and reacts in an individual way to ex-
ternal factors. This implies, that we may not recognize
smaller but relevant changes in the individual microbial
community or tend to overestimate them. The same holds
true for the predicted functions, based on 16S profiles. 16S
based microbiome studies are limited to describe changes
in the abundance of the different taxa and can only esti-
mate potential functions. Furthermore, no metabolomics
or specific cellular functions were determined. The study
was conducted in a single centre with a relatively small pa-
tient cohort, which only included patients undergoing
pancreatic surgery. The correlation of the clinical compli-
cation rates and the changes in the gut microbiome might
be influenced by heterogeneous types of complications,
primary diseases, as well as different types of operations.
Moreover, we are unable to make any conclusions regard-
ing long-term patient survival, as the study was designed
for a period of 90 days.
Conclusion
In this study, we showed that differences in the gut
microbiome are associated with the development of
postoperative complications. Thus, sequencing of the
gut microbiome or methods that take into account dif-
ferences in the NGS-defined microbial communities
might represent a useful diagnostic tool in future clinical
practice. Whether the observed changes in the gut
microbiome are a physiological defence mechanism or
represent the cause remains unclear, and this needs to
be evaluated in further investigations.
Methods
Study design
This prospective, observational, clinical study was approved
by the Ethics Committee of the Medical Faculty of Heidel-
berg (trial code no. S-119/2015; German clinical trials regis-
ter DRKS00008535). The study participants signed written
informed consent. From October 2015 to August 2016, pa-
tients undergoing pancreatic surgery were screened for eli-
gibility for study participation. Patients with an intake of
antibiotics < 6months prior to the operation, minors, preg-
nant women, allergy to antibiotics, and autoimmune or in-
flammatory intestinal diseases were excluded from the
study. In total, 32 patients met the criteria and were en-
rolled in the study. A preoperative sample was collected to
determine the baseline microbiome without surgical stress
A C B
Fig. 6 Heatmap showing the abundance score of the predicted function based on the taxonomical profile produced using Tax4Fun
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or antibiotic use, and at least two postoperative samples
were taken to evaluate the longitudinal changes in the first
10 days after the operation. All stool samples were obtained
by spontaneous defecation, without any manual stimula-
tion. Whenever complications occurred that led to pro-
longed hospitalisation, further samples were taken up to 30
days after the operation, to assess changes in the gut micro-
biome associated with the complicated clinical course. All
patients were re-evaluated for survival 90 days after the op-
eration. Each patient received a standardised single shot of
1 g sulbactam and 2 g ampicillin 30min before the surgical
procedure. Postoperatively, the participating patients were
classified into two groups consisting of those who suffered
postoperative complications and those who had a non-
complicated clinical course. The complication group was
further subdivided into patients who suffered from surgical
(e.g., bleeding, anastomotic insufficiency or pancreatic fis-
tula) or medical (e.g., pneumonia or lung artery embolism)
complications. Postoperative complications were classified
according to the Clavien-Dindo classification [28, 29].
Collection and storage of stool samples
In total, 116 stool samples from 32 patients were col-
lected and snap frozen in liquid nitrogen. Afterwards the
samples were stored at − 80 °C until further processing.
Deoxyribonucleic acid (DNA) extraction was performed
from 200-mg stool samples using the PSP® Spin Stool
DNA Kit (Stratec, Birkenfeld, Germany) according to
the manufacturer’s protocol (number 3). This ensured
isolation of total DNA from all bacteria including those
that are difficult to lyse. Negative controls involved per-
forming the extraction without any clinical sample.
Microbiome analysis
Polymerase chain reaction (PCR) was performed on total
DNA using universal bacterial primers flanking the V4 re-
gion (515F and 806R) [30], including negative controls
(from sterile water to evaluate contamination from the
PCR reagent and the negative control processed during
extraction to control carry-over from the reagent in the ex-
traction kit) to exclude contamination [31]. Sequencing
adapters were ligated to the PCR products and paired-end
sequenced using an Illumina Miseq system (250 cycles).
The raw sequences obtained from sequencing were
checked to remove low-quality sequences and chimera. To
normalise the sampling effort, sequences were subsampled
to the same number of reads per sample. Operational taxo-
nomic units (OTU) were defined using a threshold of 3%
divergence, and representative sequences were classified
at the taxonomic level by comparison with the SILVA
database (version 128) using Mothur software [32]. More
than 9 million good-quality non-chimeric reads were ob-
tained, which were subsampled to 1110 reads per sample
(Good’s coverage of 97.3%, range 94.6–99.6%). Sequencing
of a mock community of known species allowed us to cal-
culate the overall error rate of the PCR and sequencing
methodologies. The error rate was 1.89 × 10− 5 errors per
base. Sequences data are deposited in figshare (https://fig-
share.com/s/8420f9d19f0bbfa2c3f3).
Statistical analysis
Descriptive indices for alpha-diversity (non-paramet-
ric Shannon index), richness (Chao1 richness esti-
mate), dominance (relative abundance of the most
abundant OTU) and evenness (Shannon index-based
measure of evenness) were calculated from the OTU
table. Variation in alpha-diversity was tested by a
pairwise Wilcoxon sum rank test. Beta-diversity vari-
ation was evaluated via principal coordinate analysis
(PCoA) and PERMANOVA based on Morisita-Horn
similarity index [33]. Based on the PCoA distribu-
tion, cluster analysis was performed to define the
microbial communities using the ‘partitioning around
medoids’ algorithm [34]. We used Tax4Fun software to
predict the potential function present in each sample
based on the taxonomic composition [35]. We used the
package DAtest (Russel et al. 2018) to compare different
differential abundance methods and used the more accur-
ate method (based on AUC, FDR and FPR) to compare
our groups. The best method was an analysis with a model
based on a negative-binomial distribution (DESeq2) to de-
tect differences in the abundance of OTUs between the
groups [36]. All statistical analyses were performed with
MOTHUR 1.37.4 and R 3.3.0 software. A p-value of < 0.05
was considered statistically significant.
The clinical data were entered into an electronic database
(Excel 2011; Microsoft Corp., Redmond, WA, USA) and
analysed using SPSS software (version 24.0; SPSS Inc., Chi-
cago, IL, USA). Categorical data were summarised using
absolute and relative frequencies. Quantitative data were
summarised using the median and quartiles. The
Kolmogorov-Smirnov test was applied to check for normal
distribution. In the case of non-normally distributed data,
non-parametric methods were used for evaluation (chi-s-
quare test for categorical data, Mann-Whitney U test for
continuous data). Correlation analyses were performed by
calculating the Spearman rank correlation coefficient
(Spearman’s rho/ρ). A p-value of < 0.05 was considered sta-
tistically significant. Concerning symbols used to represent
higher orders of significance, p < 0.05 was indicated by *,
p < 0.01 by ** and p < 0.001 by ***.
Additional file
Additional file 1: Table S1. Patients with a malignant pancreatic tumour
(n = 19), grouped by the Union for International Cancer Control (UICC)-
Stage (Stage: I-IV) and subdivided by colonisation status (community B)
or postoperative complications. (DOCX 54 kb)
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